Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Lung Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Adenocarcinoma

Breast Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Uterine Cervical Neoplasms

Carcinoma, Renal Cell

Esophageal Squamous Cell Carcinoma

Small Cell Lung Carcinoma

Head and Neck Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Neoplasms, Squamous Cell

Carcinoma, Bronchogenic

Bronchial Neoplasms

Breast Diseases

Skin Diseases

Esophageal Neoplasms

Esophageal Diseases

Renal Cell Carcinoma

Small Cell Lung Cancer

Clear Cell Renal Cell Carcinoma

Transitional Cell Carcinoma

Esophageal Cancer

All Drugs and Chemicals

Immunomodulating Agents

OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

OncoPrism™ assay

Sara Lapomarda

Kevin Smilor

Arsheen Ali

Jarret Glasscock

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

This study will establish a prospective cohort of pre-treatment tumor specimens with correlated de-identified clinical and demographic data and tissue histology from cancer patients who are undergoing treatment with PD-1/PD-L1 inhibitors. Patients who have undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled.

The study will not require a study-specific tumor biopsy; any biopsies taken prior to treatment as part of standard of care are eligible for this study. Biopsies must not have been taken after immunotherapy treatment began.

Participants will be asked to provide their consent for the potential use of their biospecimens in subsequent studies for the development and validation of a diagnostic test.

Sections of subjects' pre-immunotherapy-treatment tumor biopsy, already collected as part of standard of care, will be collected as part of this study. Biopsy specimens may be used in subsequent studies for the development and validation of a diagnostic test.

A Multicenter Cancer Biospecimen Collection Study

Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies

No response to treatment with PD-L1/PD-1 inhibitor and response to treatment with PD-L1/PD-1 inhibitor.

Curebase Inc.

Cofactor Genomics, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Multicenter Cancer Biospecimen Collection Study	NCT04510129	Cancer of Head ... Lung Cancer, No... Small-cell Lung... Urothelial Carc... Gastroesophagea... Cervical Cancer Esophageal Squa... Triple Negative... Hepatocellular ... Renal Cell Carc... Colorectal Canc...	OncoPrism™ assa...	18 Years -	Cofactor Genomics, Inc.
A Multicenter Cancer Biospecimen Collection Study	NCT04510129	Cancer of Head ... Lung Cancer, No... Small-cell Lung... Urothelial Carc... Gastroesophagea... Cervical Cancer Esophageal Squa... Triple Negative... Hepatocellular ... Renal Cell Carc... Colorectal Canc...	OncoPrism™ assa...	18 Years -	Cofactor Genomics, Inc.

Spots Global Cancer Trial Database for oncoprism™ assay